---
title: "Sunrest Lifescience Ltd (SUNREST) — Share Price, Financials & Analysis"
symbol: "SUNREST"
company: "Sunrest Lifescience Ltd"
canonical: "https://tapetide.com/stocks/SUNREST"
isin: "INE0PLZ01012"
nse_symbol: "SUNREST"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
market_cap_cr: 63.85
generated_at: "2026-09-13T18:57:35.517Z"
---

# Sunrest Lifescience Ltd (SUNREST)

Canonical page: https://tapetide.com/stocks/SUNREST

## Company

- **NSE Symbol:** SUNREST
- **ISIN:** INE0PLZ01012
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2023-11-20
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** sunrestlifescience.com

## About

Incorporated in 2017, Sunrest Lifescience Ltd trades in Health care and Cosmetics products[1]

## Latest Price

- **Price:** ₹38.05
- **Change:** +0.85 (+2.28%)
- **Open:** ₹38.05
- **Day High:** ₹38.05
- **Day Low:** ₹38.05
- **Previous Close:** ₹37.2
- **Volume:** 1600
- **As Of:** 2026-09-11T09:49:01+00:00

## Key Fundamentals

Observed at 2026-09-11T04:36:52.925475Z.

- **Market Cap:** ₹63.85 Cr
- **Classification:** SME
- **P/E (reported):** 4
- **EPS (reported):** ₹0.53
- **Book Value:** ₹41.3
- **Price to Book:** 0.9
- **Dividend Yield:** 0%
- **ROE:** 12.36%
- **ROCE:** 14.12%
- **Debt to Equity:** 0.85
- **Revenue (yearly):** ₹33.26 Cr
- **Net Income:** ₹3.09 Cr
- **EBITDA:** ₹4.82 Cr
- **52-Week High:** ₹54
- **52-Week Low:** ₹29.55
- **RSI (14):** 48.69

## Key Insights

### Strengths

- Stock is trading at 0.80 times its book value
- Debtor days have improved from 282 to 167 days.

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 167 days.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 109.66% | 24.35% | 853.33% |
| ebitda margin growth | -40% | 59.93% | 370.45% | 244.18% |
| net income growth | 50% | 54.5% | — | 286.25% |
| revenue growth | 21.43% | 0.48% | 4.08% | 4.34% |
| roce | — | 206.96% | -74.26% | 21.67% |
| roe | — | 677.36% | 26.52% | -77.98% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2024 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- |
| Sales | 15.39 | 34.01 | 36.82 |
| Expenses | 14.48 | 31.56 | 30.07 |
| Operating Profit | 0.91 | 2.45 | 6.75 |
| OPM % | 5.91 | 7.2 | 18.33 |
| Other Income | 0 | 0 | 2.51 |
| Interest | 0.12 | 0.72 | 0.7 |
| Depreciation | 0.01 | 0.68 | 0.51 |
| Profit before tax | 0.78 | 1.05 | 8.05 |
| Tax % | 24.36 | 37.14 | 18.51 |
| Net Profit | 0.58 | 0.66 | 6.57 |
| EPS in Rs | 1.35 | 0.79 | 7.88 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2025 | Mar 2026 |
| --- | --- | --- |
| Sales | 33.41 | 70.83 |
| Expenses | 30.38 | 60.62 |
| Operating Profit | 3.03 | 10.21 |
| OPM % | 9.07 | 14.41 |
| Other Income | 0 | 2.51 |
| Interest | 0.31 | 1.42 |
| Depreciation | 0.1 | 1.19 |
| Profit before tax | 2.62 | 10.11 |
| Tax % | 23.28 | 20.87 |
| Net Profit | 2.02 | 8 |
| EPS in Rs | 4.68 | 9.6 |
| Dividend Payout % | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2025 | Mar 2026 |
| --- | --- | --- |
| Equity Capital | 4.29 | 4.29 |
| Reserves | 12.02 | 16.14 |
| Borrowings | 12.05 | 17.46 |
| Other Liabilities | 30.29 | 33.52 |
| Total Liabilities | 58.65 | 71.41 |
| Fixed Assets | 4.36 | 8.55 |
| CWIP | 0 | 0 |
| Investments | 0 | 0 |
| Other Assets | 54.29 | 62.86 |
| Total Assets | 58.65 | 71.41 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2025 | Mar 2026 |
| --- | --- | --- |
| Cash from Operating Activity | 2.92 | -0.05 |
| Cash from Investing Activity | -1.15 | -2.91 |
| Cash from Financing Activity | -0.33 | 3.99 |
| Net Cash Flow | 1.45 | 1.03 |
| Free Cash Flow | 1.76 | -2.76 |
| CFO/OP | 112 | 14 |

### Ratios

| Item | Mar 2025 | Mar 2026 |
| --- | --- | --- |
| Debtor Days | 397.34 | 167.27 |
| Inventory Days | 174.78 | 140.69 |
| Days Payable | 416.6 | 173.35 |
| Cash Conversion Cycle | 155.52 | 134.62 |
| Working Capital Days | 228.33 | 155.88 |
| ROCE % | — | 28.55 |

## Shareholding Pattern

### Quarterly

| Category | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 69.91% | 69.91% | 69.91% | 69.91% | 69.91% | 53.5% | 53.5% | 53.5% | 53.5% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 24.46% | 24.87% | 24.83% | 24.94% | 24.27% | 36.02% | 34.9% | 36.35% | 36.02% |
| Others | 5.63% | 5.22% | 5.26% | 5.15% | 5.82% | 10.48% | 11.6% | 10.14% | 10.48% |
| No. of Shareholders | 580 | 505 | 487 | 459 | 455 | 498 | 491 | 492 | 484 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Sell
- **Buy / Neutral / Sell:** 3 / 7 / 9

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 38.18 | Sell |
| EMA (10) | 38.38 | Sell |
| SMA (20) | 39.19 | Sell |
| EMA (20) | 38.46 | Sell |
| SMA (50) | 37.24 | Buy |
| EMA (50) | 37.94 | Buy |
| SMA (100) | 37.5 | Buy |
| EMA (100) | 38.25 | Sell |
| SMA (200) | 40.43 | Sell |
| EMA (200) | 40.97 | Sell |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 49.39 | Neutral |
| MACD (12,26,9) | 0.11 | Sell |
| Stochastic (14,3,3) | 32.33 | Neutral |
| ADX (14) | 17.23 | Neutral |
| Williams %R (14) | -69.5 | Neutral |
| ATR (14) | 2.25 | High Volatility |
| ROC (12) | -7.2 | Sell |
| Stoch RSI (14) | 43.69 | Neutral |
| UO (7,14,28) | 43.09 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 7 Sep - Sunrest Lifescience held its 9th AGM on 7 Sep 2026; approved financials, director reappointments and related-party transactions. | [Shareholders meeting 7 Sep - Sunrest Lifescience held its 9th AGM on 7 Sep 2026; approved financials, director reappointments and related-party transactions.](https://nsearchives.nseindia.com/corporate/SUNRESTLIFESCIENCE_07092026143601_OUTCOME_OF_AGM.pdf) |
| 7 Sep - Sunrest Lifescience filed voting results and scrutinizer report for its 9th AGM held on 7 September 2026. | [Shareholders meeting 7 Sep - Sunrest Lifescience filed voting results and scrutinizer report for its 9th AGM held on 7 September 2026.](https://nsearchives.nseindia.com/corporate/SUNRESTLIFESCIENCE_07092026164809_Scrutiniser_Report_sd.pdf) |
| 7 July 2026 - Sunrest Lifescience states corporate governance report is not applicable for quarter ended 30 June 2026. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 7 July 2026 - Sunrest Lifescience states corporate governance report is not applicable for quarter ended 30 June 2026.](https://nsearchives.nseindia.com/corporate/SUNRESTLIFESCIENCE_07072026190917_NON_APPLICABILITY_OF_CG_SD.pdf) |
| 7 July 2026 - Submitted Regulation 74(5) certificate for quarter ended 30 June 2026. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 7 July 2026 - Submitted Regulation 74(5) certificate for quarter ended 30 June 2026.](https://nsearchives.nseindia.com/corporate/SUNRESTLIFESCIENCE_07072026190328_Reg_74_5_.pdf) |
| 7 July 2026 - SDD compliance certificate filed for quarter ended 30 June 2026; nil non-compliance reported. | [Structural Digital Database 7 July 2026 - SDD compliance certificate filed for quarter ended 30 June 2026; nil non-compliance reported.](https://nsearchives.nseindia.com/corporate/SUNRESTLIFESCIENCE_07072026200736_SDD_Compliance_Certificate.pdf) |
| 7 Aug - Board approved rights issue offer documents; record date August 10, 2026, Rights Entitlement ISIN INE0PLZ20020 allotted. | [Rights Issue 7 Aug - Board approved rights issue offer documents; record date August 10, 2026, Rights Entitlement ISIN INE0PLZ20020 allotted.](https://nsearchives.nseindia.com/corporate/SUNRESTLIFESCIENCE_07082026113702_Loo_Approval_Outceome.pdf) |
| 5 Aug - Newspaper publication announces August 10, 2026 record date for rights equity share eligibility. | [Copy of Newspaper Publication 5 Aug - Newspaper publication announces August 10, 2026 record date for rights equity share eligibility.](https://nsearchives.nseindia.com/corporate/SUNRESTLIFESCIENCE_05082026145442_Newspaper.pdf) |
| 4 Aug - Record date set for 10 August 2026 rights issue, 1 equity share for every 1 held. | [Record Date 4 Aug - Record date set for 10 August 2026 rights issue, 1 equity share for every 1 held.](https://nsearchives.nseindia.com/corporate/SUNRESTLIFESCIENCE_04082026131338_RD_Intimation.pdf) |
| 4 Aug - Board approved 1:1 rights issue of 42,91,200 shares at Rs35; issue opens 18 August 2026. | [Rights Issue 4 Aug - Board approved 1:1 rights issue of 42,91,200 shares at Rs35; issue opens 18 August 2026.](https://nsearchives.nseindia.com/corporate/SUNRESTLIFESCIENCE_04082026131236_Outcome_of_02nd_Board_Meeting.pdf) |
| 30 April 2026 - Board dissolved the rights issue on 30 April 2026 due to minimum subscription shortfall and will unblock applicant funds. | [Outcome of Board Meeting 30 April 2026 - Board dissolved the rights issue on 30 April 2026 due to minimum subscription shortfall and will unblock applicant funds.](https://nsearchives.nseindia.com/corporate/SUNRESTLIFESCIENCE_30042026180704_BM_Right_Issue_Closure.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2026 from nse](https://archives.nseindia.com/annual_reports/SME_AR_30335_SUNREST_2025_2026_A_39020113_13082026192439.pdf) |
| from nse | [Annual Report 2025 from nse](https://archives.nseindia.com/annual_reports/SME_AR_28423_SUNREST_2024_2025_A_9187494_04092025161450.pdf) |
| from nse | [Annual Report 2024 from nse](https://archives.nseindia.com/annual_reports/SME_AR_25705_SUNREST_2023_2024_0409202418165.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:57:35.517Z.